Published in J Clin Endocrinol Metab on June 09, 2010
Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov (2012) 2.22
Polyphenols: benefits to the cardiovascular system in health and in aging. Nutrients (2013) 1.14
Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease. Curr Drug Metab (2010) 0.92
Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov (2006) 11.77
Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet (1992) 11.12
Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des (2009) 3.20
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev (2007) 2.45
Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res (2002) 2.05
Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology (2000) 1.98
2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res (2006) 1.70
Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res (2007) 1.63
Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol (2001) 1.33
Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res (2005) 1.33
Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol (2004) 1.23
Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol (1999) 1.21
Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun (2008) 1.16
Resveratrol inhibits foam cell formation via NADPH oxidase 1- mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med (2009) 1.12
Sirtuin activators. Expert Opin Ther Pat (2009) 1.10
Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vasc Surg (2005) 1.10
Cardiovascular protective effects of 17beta-estradiol metabolites. J Appl Physiol (1985) (2001) 1.04
Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler Thromb Vasc Biol (2000) 1.04
Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res (2006) 1.01
Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci (2000) 0.94
CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension (2002) 0.94
Is resveratrol an estrogen agonist in growing rats? Endocrinology (1999) 0.89
Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci (1996) 0.88
Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: direct evidence from catechol-O-methyltransferase-knockout mice. Circulation (2003) 0.86
Differential mechanisms of Ca(2+) release from vascular smooth muscle cell microsomes. Exp Biol Med (Maywood) (2002) 0.86
Potential pro-inflammatory action of resveratrol in vascular smooth muscle cells from normal and diabetic rats. Nutr Metab Cardiovasc Dis (2005) 0.85
Increased 2-methoxyestradiol production in human coronary versus aortic vascular cells. Hypertension (2001) 0.82
Resveratrol supplementation worsen the dysregulation of genes involved in hepatic lipid homeostasis observed in hyperhomocysteinemic mice. Food Chem Toxicol (2008) 0.79
Wine constituents inhibit thrombosis but not atherogenesis in C57BL/6 apolipoprotein E-deficient mice. Br J Nutr (2006) 0.78
Estrogen metabolism in primary kidney cell cultures from Syrian hamsters. J Steroid Biochem (1990) 0.77
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J Fam Plann Reprod Health Care (2013) 2.07
Sex hormones and hypertension. Cardiovasc Res (2002) 1.74
Blast exposure in rats with body shielding is characterized primarily by diffuse axonal injury. J Neurotrauma (2011) 1.71
2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res (2006) 1.70
Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 1.70
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res (2005) 1.51
Conversion of tibolone to 7alpha-methyl-ethinyl estradiol using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry: interpretation and clinical implications. Menopause (2006) 1.38
Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab (2006) 1.37
Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J Neurotrauma (2007) 1.34
Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol (2005) 1.26
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res (2007) 1.20
Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther (2003) 1.18
2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol (2006) 1.17
Assessment of nerve stimulation-induced release of purines from mouse kidneys by tandem mass spectrometry. J Pharmacol Exp Ther (2008) 1.17
Identification and quantification of 2',3'-cAMP release by the kidney. J Pharmacol Exp Ther (2008) 1.14
cAMP-adenosine pathway in the proximal tubule. J Pharmacol Exp Ther (2006) 1.13
Influence of childhood sexual abuse on pregnancy, delivery, and the early postpartum period in adult women. J Psychosom Res (2006) 1.12
Complexities of oestradiol pharmacology in pulmonary arterial hypertension. Eur Respir J (2013) 1.11
Extracellular 2,3-cyclic adenosine monophosphate is a potent inhibitor of preglomerular vascular smooth muscle cell and mesangial cell growth [corrected]. Hypertension (2010) 1.10
Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab (2009) 1.07
Adenosine receptor expression and function in bladder uroepithelium. Am J Physiol Cell Physiol (2006) 1.07
Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J Neurotrauma (2004) 1.07
1,3,7-trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J Immunol (2007) 1.04
Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice. J Neurotrauma (2010) 1.04
Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5'-monophosphate. J Immunol (2009) 1.03
Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells. Cancer Res (2006) 1.03
Screening of biochemical and molecular mechanisms of secondary injury and repair in the brain after experimental blast-induced traumatic brain injury in rats. J Neurotrauma (2013) 0.99
Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol (2005) 0.99
A(2B) adenosine receptors stimulate growth of porcine and rat arterial endothelial cells. Hypertension (2002) 0.98
Alpha2-adrenoceptors enhance angiotensin II-induced renal vasoconstriction: role for NADPH oxidase and RhoA. Hypertension (2008) 0.96
Murine orthostatic response during prolonged vertical studies: effect on cerebral blood flow measured by arterial spin-labeled MRI. Magn Reson Med (2005) 0.96
2',3'-cAMP, 3'-AMP, and 2'-AMP inhibit human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors. Am J Physiol Heart Circ Physiol (2011) 0.96
Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection. Hypertension (2010) 0.96
Expression of the 2',3'-cAMP-adenosine pathway in astrocytes and microglia. J Neurochem (2011) 0.95
Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. Clin Endocrinol (Oxf) (2007) 0.95
2'-AMP and 3'-AMP inhibit proliferation of preglomerular vascular smooth muscle cells and glomerular mesangial cells via A2B receptors. J Pharmacol Exp Ther (2011) 0.95
CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension (2002) 0.94
Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction. Hypertension (2005) 0.94
CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology (2012) 0.94
Extracellular 3',5'-cAMP-adenosine pathway inhibits glomerular mesangial cell growth. J Pharmacol Exp Ther (2010) 0.94
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J Mol Med (Berl) (2014) 0.94
Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children. Neurosurgery (2004) 0.93
2-Methoxyestradiol: a potential treatment for multiple proliferative disorders. Endocrinology (2007) 0.93
Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev (2006) 0.93
Consequences of childhood sexual abuse experiences on dental care. J Psychosom Res (2007) 0.93
2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats. J Cardiovasc Pharmacol (2007) 0.93
Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol (2013) 0.92
alpha 2-Adrenoceptors potentiate angiotensin II- and vasopressin-induced renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther (2003) 0.92
Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension (2002) 0.92
Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension (2004) 0.92
Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother (2010) 0.92
Adenosine inhibits PDGF-induced growth of human glomerular mesangial cells via A(2B) receptors. Hypertension (2005) 0.92
Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells. Hypertension (2002) 0.92
The brain in vivo expresses the 2',3'-cAMP-adenosine pathway. J Neurochem (2012) 0.92
The β-blocker Nebivolol Is a GRK/β-arrestin biased agonist. PLoS One (2013) 0.91
Cytochromes 1A1/1B1- and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. J Clin Endocrinol Metab (2004) 0.91
A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation (2007) 0.91
Role of renal sympathetic nerves in regulating renovascular responses to angiotensin II in spontaneously hypertensive rats. J Pharmacol Exp Ther (2006) 0.91
BMI: new aspects of a classical risk factor for hypertensive disorders in pregnancy. Clin Sci (Lond) (2006) 0.91
In vivo hypoxic preconditioning protects from warm liver ischemia-reperfusion injury through the adenosine A2B receptor. Transplantation (2012) 0.90
Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol Res (2006) 0.90
The pancreatohepatorenal cAMP-adenosine mechanism. J Pharmacol Exp Ther (2007) 0.90